Survival curves of NPM1-mutated AML patients (NK vs AK) from the GIMEMA LAM99P and GIMEMA/EORTC AML12 trials. (A) No significant differences in OS are observed between NPM1-mutated AML with NK and AK (P = .877). (B) No significant differences in EFS are observed between NPM1-mutated AML with NK and AK (P = .827). (C) No significant differences in OS are observed between NPM1-mutated/FLT3-ITD⁻ AML with NK and AK (P = .814). (D) No significant differences in EFS are observed between NPM1-mutated/FLT3-ITD⁻ AML with NK and AK (P = .970).